Journals / Anatolian Journal of Emergency Medicine / 2020 / Cilt: 3 - Sayı: 2

Emergency Service Management of Bleeding Due to New Generation Oral Anticoagulant

Yeni Kuşak Oral Antikoagülanlara Bağlı Kanamalarda Acil Servis Yönetimi

Pages
62–65
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, the emergency service management of patients with bleeding associated with the use of NOAC drugs will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:New generation oral anticoagulant (NOAC) drugs are widely used today, as they have more advantages in some clinical situations and they do not require close monitoring for their dosage.
📊
Key Findings & Data:Rarely, they increase the risk of bleeding like the other anticoagulant drugs and are not able to be monitored in the high dose intakes.
💡
Conclusion & Impact:In this article, the emergency service management of patients with bleeding associated with the use of NOAC drugs will be discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

New generation oral anticoagulant (NOAC) drugs are widely used today, as they have more advantages in some clinical situations and they do not require close monitoring for their dosage. Rarely, they increase the risk of bleeding like the other anticoagulant drugs and are not able to be monitored in the high dose intakes. Due to these reasons, the management of these patients in emergency department should be specific. In this article, the emergency service management of patients with bleeding associated with the use of NOAC drugs will be discussed.

Özet

Bazı klinik durumlarda avantajlı oldukları ve dozları açısından yakın izlem gerektirmedikleri için yeni kuşak oral antikoagülan (YOAK) ilaçlar günümüzde yaygın olarak kullanılmaktadır.Nadir de olsa tüm antikoagülan ilaçlar gibi kanama riskini arttırırlar ve yüksek doz maruziyetlerinde laboratuvar olarak monitörizasyonları mümkün değildir. Bu yüzden hastaların acil serviste yönetimi özellik arz etmektedir.Bu yazıda YOAK kullanımına bağlı kanamalı hastaların acil servis yönetiminden bahsedilecektir.

🔖

Cite This Article

Durak, V. A., Köksal, Ö. (2022). Emergency Service Management of Bleeding Due to New Generation Oral Anticoagulant. Anatolian Journal of Emergency Medicine, Cilt: 3 - Sayı: 2, 62–65. https://ajindex.com/articles/439364

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with two doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72
  2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151
  3. Levine M, Goldstein JH. Bleeding complications of targeted oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2014;1:504-509
  4. Levine M, Pizon AF, Padilla-Jones A, et al. Warfarin overdose: a 25 year experience. J Med Toxicol. 2014;10:156-164
  5. Pfeiffer H, Herbst L, Schwarze B, et al. Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: a case report. Medicine (Baltimore). 2016;95:e5343
  6. Repplinger DJ, Hoffman RS, Nelson LS, et al. Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations. Clin Toxicol. 2016;54:647-649
  7. Lehmann T, Hofer KE, Baumann M, et al. Massive human rivaroxaban overdose. Thromb Haemost. 2014;112:834-836
  8. Sajkov D, Gallus A. Accidental rivaroxaban overdose in a patient with pulmonary embolism: some lessons for managing new oral anticoagulants. Clin Med Insights Case Rep. 2015;8:57-59
  9. Barton J, Wong A, Graudins A. Anti-X activity in apixaban overdose: a case report. Clin Toxicol (Phila). 2016;54:871-873
  10. Peetermans M, Pollack CJr, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol (Phila). 2016;54:644-646
  11. Shapiro S, Bhatnagar N, Khan A, et al. Idarucizumab for dabigatran overdose in a child. Br J Haematol. 2018;180(3):457-459. doi: 10.1111/bjh.14371
  12. Vlad I, Armstrong J, Ridgley J, et al. Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. Clin Toxicol (Phila). 2016;54:286-289
  13. Mumoli N, Cei M, Fiorini M, et al. Conservative management of intentional massive dabigatran overdose. Blood Coagul Fibrinolysis. 2015;26:225-229
  14. Chiew AL, Khamoudes D, Chan BS, et al. Use of continuous veno- venous haemodiafiltration therapy in dabigatran overdose. Clin Toxicol (Phila). 2014;52:283-287
  15. Woo JS, Kapadia N, Phanco SE, et al. Positive outcome after intentional overdose of dabigatran. J Med Toxicol. 2013;9:192-195
  16. Kocabay G, Okcular I, Akkaya V, et al. Suicide attempt with clopidogrel. Hum Exp Toxicol. 2006;25:731-734
  17. Michael